Preclinical Study Data on TTX-MC138 for Glioblastoma Accepted for Publication
source: shutterstock.com

Preclinical Study Data on TTX-MC138 for Glioblastoma Accepted for Publication

TransCode Therapeutics, Inc. (“TransCode”) was founded with a mission to revolutionize the cancer treatment landscape and improve patient outcomes. The company is currently working to uphold this mission through the…

Continue Reading Preclinical Study Data on TTX-MC138 for Glioblastoma Accepted for Publication
Axitinib-Avelumab Combination Prompted Responses in Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
mcmurryjulie / Pixabay

Axitinib-Avelumab Combination Prompted Responses in Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

While the five-year survival rate for adenoid cystic carcinoma (ACC) is relatively high, this cancer has a high risk of recurrence. Therapeutic options are needed to manage this cancer and…

Continue Reading Axitinib-Avelumab Combination Prompted Responses in Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 2)
Photo courtesy of Brittany

Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 2)

Before you read further, make sure to check out Part 1 of our interview, where Brittany discusses what non-small cell lung cancer (NSCLC) is, her diagnostic journey, and how she learned that…

Continue Reading Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 2)
Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 1)
Photo courtesy of Brittany

Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 1)

On the one-year anniversary of her RET+ non-small cell lung cancer (NSCLC) diagnosis, 37-year-old Brittany Hawkins had spent some time reflecting on her journey. When she was just seventeen years…

Continue Reading Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 1)